{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:05:47Z","timestamp":1779919547713,"version":"3.53.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2025.12.027","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:27:31Z","timestamp":1768249651000},"page":"e144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Oscar Buisan, Pol Servian, Sonia Pedre\u00f1o-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Gu\u00e9rin Response in Non\u2013muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. 2026;89:114\u2013120"],"prefix":"10.1016","volume":"89","author":[{"given":"Harry","family":"Herr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.12.027_b0005","doi-asserted-by":"crossref","unstructured":"Buisan O, Servian P, Pedre\u00f1o-Lopez S, et al. A novel heterologous prime-boost strategy using RUTI vaccine to improve the bacillus Calmette-Gu\u00e9rin response in non\u2013muscle-invasive bladder cancer patients: phase 1 RUTIVAC-1 trial. Eur Urol 2026;89:114\u201320.","DOI":"10.1016\/j.eururo.2025.08.014"},{"key":"10.1016\/j.eururo.2025.12.027_b0010","doi-asserted-by":"crossref","unstructured":"Meeks JJ. \u201cPrime\u201d time for boosting the immune response to bacillus Calmette-Gu\u00e9rin. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4166.","DOI":"10.1016\/j.eururo.2025.09.4166"},{"key":"10.1016\/j.eururo.2025.12.027_b0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical BCG therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.12.027_b0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2025.12.027_b0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","article-title":"Systemic immune response after intravesical instillation of BCG for superficial bladder cancer","volume":"115","author":"Taniguchi","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2025.12.027_b0030","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2023.6804","article-title":"Response to 2 induction courses of BCG therapy among patients with high-risk non-muscle-invasive bladder cancer. 5-year follow-up of a phase 2 clinical trial","volume":"10","author":"Katims","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:16Z","timestamp":1779917656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825048973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0302283825048973"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Oscar Buisan, Pol Servian, Sonia Pedre\u00f1o-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Gu\u00e9rin Response in Non\u2013muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. 2026;89:114\u2013120","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}